Helicobacter pylori infection: New pathogenetic and clinical aspects

Abstract

Helicobacter pylori (H. pylori) infects more than half of the world’s human population, but only 1% to 3% of infected people consequently develop gastric adenocarcinomas. The clinical outcome of the infection is determined by host genetic predisposition, bacterial virulence factors, and environmental factors. The association between H. pylori infection and chronic active gastritis, peptic ulcer disease, gastric cell carcinoma, and B cell mucosa-associated lymphoid tissue lymphoma has been well established. With the exception of unexplained iron deficiency anemia and idiopathic thrombocytopenic purpura, H. pylori infection has no proven role in extraintestinal diseases. On the other hand, there is data showing that H. pylori infection could be beneficial for some human diseases. The unpredictability of the long-term consequences of H. pylori infection and the economic challenge in eradicating it is why identification of high-risk individuals is crucial.

Keywords: Helicobacter pylori, Virulence factor, Host factors, Gastroduodenal diseases, Extraintestinal disorders

Core tip:Helicobacter pylori (H. pylori) infects more than half of the world’s human population. The association between H. pylori infection and chronic active gastritis, peptic ulcer disease, gastric cell carcinoma, and B cell mucosa-associated lymphoid tissue lymphoma, unexplained iron deficiency anemia and idiopathic thrombocytopenic purpura has been well established. H. pylori screening and treatment is a recommended gastric cancer risk reduction strategy in high-risk populations. The unpredictability of the long-term consequences of H. pylori infection and the economic challenge in eradicating it is why identification of high-risk individuals is crucial.